Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Spero Therapeutics, Inc. (SPRO)
Price$1.23Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.6M | $371,000 | $933,000 | $2.5M | $3.1M | $258,000 | $4.7M | $4.0M | $2.0M | $335,000 | — |
| Research & development | $38.5M | $96.8M | $51.4M | $47.6M | $64.5M | $67.0M | $65.8M | $33.9M | $32.9M | $26.3M | $11.1M |
| Operating expenses | $60.5M | $121.3M | $82.3M | $95.7M | $106.2M | $88.4M | $81.4M | $46.8M | $43.7M | $33.6M | $13.3M |
| Operating income | $6.3M | −$73.4M | $21.5M | −$42.2M | −$88.0M | −$79.1M | −$63.2M | −$42.8M | −$41.7M | −$33.2M | −$13.3M |
| Operating margin | 50.17% | −19,773.85% | 2,302.36% | −1,685.86% | −2,865.50% | −30,663.95% | −1,333.11% | −1,079.32% | −2,108.64% | −9,916.72% | — |
| EBITDA | $6.3M | −$73.4M | $21.8M | −$41.3M | −$87.3M | −$78.4M | −$62.5M | −$42.4M | −$41.4M | −$32.9M | −$13.3M |
| EBITDA margin | 50.17% | −19,773.32% | 2,341.69% | −1,651.14% | −2,844.46% | −30,368.99% | −1,317.29% | −1,069.01% | −2,090.30% | −9,833.43% | — |
| Net income | $8.6M | −$68.6M | $22.8M | −$46.4M | −$89.8M | −$78.3M | −$60.9M | −$41.7M | −$38.7M | −$25.5M | −$10.2M |
| Net profit margin | 68.11% | −18,481.40% | 2,444.37% | −1,854.37% | −2,925.08% | −30,348.84% | −1,284.27% | −1,051.44% | −1,957.71% | −7,609.25% | — |
| Basic EPSper basic share | $0.15 | -$1.27 | $0.43 | -$1.23 | -$2.91 | -$3.52 | -$3.35 | -$2.60 | -$17.82 | -$95.87 | -$53.11 |
| Diluted EPSper diluted share | $0.15 | -$1.27 | $0.43 | -$1.23 | -$2.91 | -$3.52 | -$3.35 | -$2.60 | -$17.82 | -$95.87 | -$53.11 |
Owners
Reported shareholders
15.81%of listed shares
GSK plc9.19M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
GSK plc | 15.81%9.19M shares |
Pfizer Inc | 4.06%2.36M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.50%2.04M shares |
Shukla Sath | ≈2.99%1.74M shares |
Rajavelu Esther | ≈1.70%986.85K shares |
RENAISSANCE TECHNOLOGIES LLC | 1.63%947.9K shares |
Alphabet Inc. | 1.53%889.98K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.31%759.29K shares |
Keutzer Timothy | ≈1.28%742.51K shares |
Mahadevia Ankit | ≈1.21%703.29K shares |
BlackRock, Inc. | 1.02%594.4K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.97%566.33K shares |
RAYMOND JAMES FINANCIAL INC | 0.90%521.71K shares |
TWO SIGMA INVESTMENTS, LP | 0.66%382.81K shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.57%332.97K shares |
VANGUARD FIDUCIARY TRUST CO | 0.49%287.65K shares |
GSA CAPITAL PARTNERS LLP | 0.49%285.91K shares |
DIMENSIONAL FUND ADVISORS LP | 0.47%274.82K shares |
GOLDMAN SACHS GROUP INC | 0.44%256.99K shares |
STATE STREET CORP | 0.37%214.75K shares |
Percentages use 58.15M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 4, 2026Form 4 | Rajavelu EstherSee Remarks | SellCommon Stock | 25.2K | $2.51 | $63.4K | 986.9K |
| Feb 6, 2026Form 4 | Rajavelu EstherSee Remarks | SellCommon Stock | 50.8K | $2.36 | $119.9K | 1.01M |
| Feb 6, 2026Form 4 | Rajavelu EstherSee Remarks | SellCommon Stock | 37.1K | $2.36 | $87.6K | 1.06M |
| Feb 6, 2026Form 4 | Keutzer TimothyChief Operating Officer | SellCommon Stock | 18.7K | $2.36 | $44.0K | 742.5K |
| Feb 4, 2026Form 4 | Keutzer TimothyChief Operating Officer | SellCommon Stock | 3.5K | $2.24 | $7.8K | 761.2K |